Abstract |
The avian H5N1 influenza virus has the potential to cause a new pandemic. Since it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to produce vaccines that confer cross-protective immunity. Mucosal vaccine administration was reported to induce cross-protective immunity by inducing secretion of IgA at the mucosal surface. Adjuvants can also enhance the development of fully protective mucosal immunity. Here we show that a new mucosal adjuvant, poly I:poly C12U ( Ampligen), a Toll-like receptor 3 agonist proven to be safe in a Phase III human trial, is an effective adjuvant for H5N1 influenza vaccination. Intranasal administration of a candidate influenza vaccine with Ampligen resulted in secretion of IgA, and protected mice that were subsequently challenged with homologous A/Vietnam/1194/2004 and heterologous A/HK/483/97 and A/Indonesia/6/2005 virus.
|
Authors | Takeshi Ichinohe, Akira Kawaguchi, Shin-ichi Tamura, Hidehiro Takahashi, Hirofumi Sawa, Ai Ninomiya, Masaki Imai, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Joe Chiba, Tetsutaro Sata, Takeshi Kurata, Hideki Hasegawa |
Journal | Microbes and infection
(Microbes Infect)
Vol. 9
Issue 11
Pg. 1333-40
(Sep 2007)
ISSN: 1286-4579 [Print] France |
PMID | 17890128
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Viral
- Immunoglobulin A
- Immunoglobulin G
- Influenza Vaccines
- Poly U
- poly(I).poly(c12,U)
- Poly I-C
|
Topics |
- Administration, Intranasal
- Animals
- Antibodies, Viral
(analysis)
- Blood
(virology)
- Female
- Immunoglobulin A
(analysis)
- Immunoglobulin G
(blood)
- Influenza A Virus, H5N1 Subtype
(immunology)
- Influenza Vaccines
(administration & dosage, immunology)
- Mice
- Mice, Inbred BALB C
- Nasal Lavage Fluid
(immunology)
- Orthomyxoviridae Infections
(prevention & control)
- Poly I-C
(administration & dosage, immunology)
- Poly U
(administration & dosage, immunology)
|